Literature DB >> 2669920

Treatment decisions in advanced ovarian cancer.

M M Cody1, M L Slevin.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2669920      PMCID： PMC2247045          DOI： 10.1038/bjc.1989.241

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  8 in total

1.  Second-line chemotherapy for ovarian cancer.

Authors:  G R Weiss
Journal:  Clin Obstet Gynecol       Date:  1986-09       Impact factor: 2.190

Review 2.  Chemotherapy of ovarian cancer.

Authors:  R F Ozols; R C Young
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

3.  Patient attitudes to chemotherapy for advanced gastro-intestinal cancer.

Authors:  I R Gough; C M Furnival; W Burnett
Journal:  Clin Oncol       Date:  1981-03

4.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

Authors:  R C Young; B A Chabner; S P Hubbard; R I Fisher; R A Bender; T Anderson; R M Simon; G P Canellos; V T DeVita
Journal:  N Engl J Med       Date:  1978-12-07       Impact factor: 91.245

5.  Role of cytoreductive surgical treatment in the management of advanced ovarian cancer.

Authors:  C T Griffiths; L M Parker; A F Fuller
Journal:  Cancer Treat Rep       Date:  1979-02

6.  On the receiving end--patient perception of the side-effects of cancer chemotherapy.

Authors:  A Coates; S Abraham; S B Kaye; T Sowerbutts; C Frewin; R M Fox; M H Tattersall
Journal:  Eur J Cancer Clin Oncol       Date:  1983-02

7.  Depressive illness and lung cancer. II. Follow-up of inoperable patients.

Authors:  J E Hughes
Journal:  Eur J Surg Oncol       Date:  1985-03       Impact factor: 4.424

8.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

Authors:  G Blackledge; F Lawton; C Redman; K Kelly
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640
  8 in total
  2 in total

Review 1.  An overview in the treatment of advanced ovarian cancer. MRC Gynaecological Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

2.  The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Authors:  J Fisken; R C Leonard; M Stewart; G J Beattie; C Sturgeon; L Aspinall; J E Roulston
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.